Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Exelixis, Inc. (EXEL) since 2002 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Exelixis, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 939767.
Total stock buying since 2002: $19,172,979.
Total stock sales since 2002: $314,392,814.
Total stock option exercises since 2002: $121,154,617.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 735,666 | $30,976,923 | 832,087 | $16,164,336 |
| 2024 | 615,000 | $12,666,910 | 872,432 | $24,870,534 | 1,184,849 | $27,369,242 |
| 2023 | 120,409 | $2,602,038 | 790,011 | $15,720,431 | 955,000 | $12,029,098 |
| 2022 | 0 | $0 | 436,562 | $8,413,845 | 525,000 | $2,574,050 |
| 2021 | 0 | $0 | 1,335,658 | $29,298,416 | 1,610,000 | $5,472,649 |
| 2020 | 0 | $0 | 2,145,329 | $47,948,063 | 4,262,623 | $19,133,251 |
| 2019 | 0 | $0 | 2,360,470 | $50,493,429 | 1,819,929 | $9,680,173 |
| 2018 | 0 | $0 | 1,561,698 | $32,260,917 | 1,448,858 | $7,586,210 |
| 2017 | 0 | $0 | 2,246,867 | $53,251,678 | 1,895,509 | $9,574,264 |
| 2016 | 60,000 | $297,920 | 795,219 | $11,897,846 | 1,152,332 | $8,539,362 |
| 2015 | 100,000 | $488,549 | 352,425 | $2,055,775 | 357,633 | $1,984,151 |
| 2014 | 20,000 | $34,200 | 0 | $0 | 23,914 | $0 |
| 2013 | 10,000 | $51,400 | 0 | $0 | 54,270 | $0 |
| 2012 | 35,000 | $156,795 | 7,000 | $35,917 | 54,271 | $0 |
| 2011 | 0 | $0 | 0 | $0 | 121,327 | $0 |
| 2010 | 482,700 | $1,489,754 | 108,539 | $835,207 | 104,427 | $570,120 |
| 2009 | 0 | $0 | 33,835 | $208,447 | 12,500 | $63,000 |
| 2008 | 392,500 | $1,276,125 | 27,213 | $188,239 | 0 | $0 |
| 2007 | 0 | $0 | 119,375 | $1,276,190 | 0 | $0 |
| 2006 | 0 | $0 | 205,624 | $2,114,980 | 65,624 | $414,711 |
| 2005 | 0 | $0 | 325,458 | $2,545,977 | 0 | $0 |
| 2004 | 10,000 | $85,388 | 0 | $0 | 0 | $0 |
| 2002 | 2,000 | $23,900 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-09-15 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 47,500 | 20.46 | 971,850 |
| 2021-09-15 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 47,500 | 6.21 | 294,975 |
| 2021-08-16 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 55,000 | 18.44 | 1,014,200 |
| 2021-08-16 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 55,000 | 1.90 | 104,500 |
| 2021-07-26 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Option Ex | 40,000 | 4.20 | 168,000 |
| 2021-07-21 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Option Ex | 35,000 | 4.20 | 147,000 |
| 2021-07-15 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 60,000 | 17.47 | 1,048,199 |
| 2021-07-15 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 60,000 | 1.90 | 114,000 |
| 2021-07-06 | Cohen Charles | Option Ex | 80,000 | 4.71 | 377,200 |
| 2021-06-17 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 60,000 | 22.18 | 1,330,800 |
| 2021-06-17 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 60,000 | 1.90 | 114,000 |
| 2021-05-18 | Haley Patrick J. (EVP, Commercial) | Sale | 14,593 | 24.73 | 360,884 |
| 2021-05-17 | Hessekiel Jeffrey (EVP, General Counsel & Sec) | Sale | 18,000 | 25.39 | 457,020 |
| 2021-05-14 | Marchesi Vincent T | Sale | 40,000 | 25.04 | 1,001,600 |
| 2021-05-14 | Marchesi Vincent T | Option Ex | 40,000 | 6.30 | 252,000 |
| 2021-05-14 | Poste George | Sale | 40,802 | 24.97 | 1,018,825 |
| 2021-05-13 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Sale | 100,000 | 25.38 | 2,538,000 |
| 2021-05-13 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Option Ex | 100,000 | 1.90 | 190,000 |
| 2021-05-12 | Morrissey Michael (President and CEO) | Option Ex | 50,000 | 4.20 | 210,000 |
| 2021-05-11 | Freire Maria C | Sale | 8,275 | 25.01 | 206,957 |
| 2021-05-11 | Papadopoulos Stelios | Sale | 20,770 | 24.99 | 518,979 |
| 2021-05-11 | Papadopoulos Stelios | Option Ex | 120,000 | 4.27 | 512,399 |
| 2021-04-26 | Haley Patrick J. (EVP, Commercial) | Sale | 7,665 | 25.03 | 191,854 |
| 2021-04-26 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Sale | 50,000 | 25.00 | 1,250,000 |
| 2021-04-26 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Option Ex | 50,000 | 1.70 | 85,000 |
| 2021-03-29 | Wyszomierski Jack L | Sale | 6,220 | 22.64 | 140,820 |
| 2021-03-29 | Wyszomierski Jack L | Option Ex | 40,000 | 3.38 | 135,200 |
| 2021-03-15 | Garber Alan M | Sale | 40,000 | 23.60 | 944,000 |
| 2021-03-15 | Garber Alan M | Option Ex | 40,000 | 3.38 | 135,200 |
| 2021-03-01 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 65,000 | 22.11 | 1,437,150 |
| 2021-03-01 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 65,000 | 1.70 | 110,500 |
| 2021-02-24 | Cohen Charles | Sale | 40,000 | 22.69 | 907,600 |
| 2021-02-24 | Cohen Charles | Option Ex | 40,000 | 3.38 | 135,200 |
| 2021-02-23 | Willsey Lance | Sale | 40,000 | 22.13 | 885,200 |
| 2021-02-23 | Willsey Lance | Option Ex | 40,000 | 3.38 | 135,200 |
| 2021-02-22 | Marchesi Vincent T | Sale | 24,097 | 22.29 | 537,122 |
| 2021-02-22 | Poste George | Option Ex | 40,000 | 3.38 | 135,200 |
| 2021-02-18 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Sale | 50,000 | 22.35 | 1,117,500 |
| 2021-02-18 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Option Ex | 50,000 | 1.70 | 85,000 |
| 2021-02-17 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Sale | 50,000 | 22.50 | 1,125,000 |
| 2021-02-17 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Option Ex | 50,000 | 1.70 | 85,000 |
| 2021-02-16 | Feldbaum Carl B | Sale | 20,000 | 21.96 | 439,200 |
| 2021-02-16 | Feldbaum Carl B | Option Ex | 20,000 | 3.38 | 67,600 |
| 2021-02-16 | Willsey Lance | Sale | 50,000 | 21.90 | 1,095,000 |
| 2021-02-12 | Haley Patrick J. (EVP, Commercial) | Sale | 45,000 | 21.57 | 970,650 |
| 2021-02-01 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 65,000 | 22.08 | 1,435,200 |
| 2021-02-01 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 65,000 | 1.70 | 110,500 |
| 2021-01-12 | Senner Christopher J. (EVP and CFO) | Sale | 30,000 | 25.00 | 750,000 |
| 2021-01-12 | Senner Christopher J. (EVP and CFO) | Option Ex | 30,000 | 3.66 | 109,800 |
| 2021-01-04 | Hessekiel Jeffrey (EVP and General Counsel) | Option Ex | 50,000 | 4.58 | 229,250 |
| 2021-01-04 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 65,000 | 20.32 | 1,320,800 |
| 2021-01-04 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 65,000 | 1.70 | 110,500 |
| 2020-12-18 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 65,000 | 20.01 | 1,300,650 |
| 2020-12-18 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 65,000 | 1.70 | 110,500 |
| 2020-12-04 | Willsey Lance | Option Ex | 106,142 | 5.82 | 617,746 |
| 2020-11-24 | Marchesi Vincent T | Sale | 40,004 | 18.50 | 740,074 |
| 2020-11-24 | Marchesi Vincent T | Option Ex | 40,004 | 5.82 | 232,823 |
| 2020-11-15 | Hessekiel Jeffrey (EVP and General Counsel) | Option Ex | 30,000 | 7.27 | 218,100 |
| 2020-11-10 | Wyszomierski Jack L | Sale | 34,000 | 20.61 | 700,740 |
| 2020-11-10 | Wyszomierski Jack L | Option Ex | 62,403 | 5.82 | 363,185 |
| 2020-10-21 | Hessekiel Jeffrey (EVP and General Counsel) | Sale | 39,742 | 21.95 | 872,336 |
| 2020-10-21 | Hessekiel Jeffrey (EVP and General Counsel) | Option Ex | 39,742 | 7.27 | 288,924 |
| 2020-10-08 | Senner Christopher J. (EVP and CFO) | Sale | 10,000 | 25.00 | 250,000 |
| 2020-10-08 | Senner Christopher J. (EVP and CFO) | Option Ex | 10,000 | 3.66 | 36,600 |
| 2020-09-22 | Hessekiel Jeffrey (EVP and General Counsel) | Sale | 10,258 | 26.14 | 268,144 |
| 2020-09-22 | Hessekiel Jeffrey (EVP and General Counsel) | Option Ex | 10,258 | 7.27 | 74,575 |
| 2020-09-21 | Haley Patrick J. (EVP, Commercial) | Sale | 4,680 | 26.09 | 122,101 |
| 2020-09-21 | Haley Patrick J. (EVP, Commercial) | Option Ex | 4,680 | 5.82 | 27,237 |
| 2020-09-16 | Hessekiel Jeffrey (EVP and General Counsel) | Sale | 20,000 | 26.11 | 522,200 |
| 2020-09-16 | Hessekiel Jeffrey (EVP and General Counsel) | Option Ex | 20,000 | 7.27 | 145,400 |
| 2020-09-15 | Senner Christopher J. (EVP and CFO) | Sale | 20,000 | 25.00 | 500,000 |
| 2020-09-15 | Senner Christopher J. (EVP and CFO) | Option Ex | 20,000 | 3.66 | 73,200 |
| 2020-09-08 | Hessekiel Jeffrey (EVP and General Counsel) | Option Ex | 249,692 | 4.05 | 1,012,501 |
| 2020-09-01 | Cohen Charles | Option Ex | 115,396 | 5.82 | 671,604 |
| 2020-08-14 | Poste George | Option Ex | 29,662 | 5.82 | 172,632 |
| 2020-07-20 | Haley Patrick J. (EVP, Commercial) | Sale | 3,151 | 25.36 | 79,909 |
| 2020-07-20 | Morrissey Michael (President and CEO) | Option Ex | 100,000 | 6.21 | 621,000 |
| 2020-07-10 | Morrissey Michael (President and CEO) | Option Ex | 100,000 | 6.21 | 621,000 |
| 2020-06-19 | Morrissey Michael (President and CEO) | Option Ex | 100,000 | 6.21 | 621,000 |
| 2020-06-08 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 26,000 | 22.56 | 586,560 |
| 2020-06-08 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 26,000 | 5.51 | 143,260 |
| 2020-06-04 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Sale | 100,000 | 22.96 | 2,296,000 |
| 2020-06-04 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Option Ex | 100,000 | 1.70 | 170,000 |
| 2020-05-29 | Morrissey Michael (President and CEO) | Option Ex | 100,000 | 6.21 | 621,000 |
| 2020-05-22 | Garber Alan M | Sale | 36,111 | 24.42 | 881,830 |
| 2020-05-21 | Marchesi Vincent T | Sale | 40,000 | 24.64 | 985,600 |
| 2020-05-21 | Marchesi Vincent T | Option Ex | 40,000 | 5.82 | 232,800 |
| 2020-05-20 | Haley Patrick J. (EVP, Commercial) | Sale | 3,151 | 24.99 | 78,743 |
| 2020-05-18 | Willsey Lance | Sale | 30,000 | 26.26 | 787,800 |
| 2020-05-18 | Willsey Lance | Option Ex | 30,000 | 4.58 | 137,400 |
| 2020-05-18 | Scangos George A | Sale | 75,000 | 25.96 | 1,947,000 |
| 2020-05-15 | Scangos George A | Option Ex | 51,686 | 5.20 | 268,767 |
| 2020-05-15 | Morrissey Michael (President and CEO) | Option Ex | 100,000 | 6.21 | 621,000 |
| 2020-05-14 | Willsey Lance | Sale | 15,000 | 25.26 | 378,900 |
| 2020-05-14 | Willsey Lance | Option Ex | 15,000 | 5.92 | 88,800 |
| 2020-05-13 | Hessekiel Jeffrey (EVP and General Counsel) | Option Ex | 25,000 | 1.70 | 42,500 |
| 2020-05-13 | Papadopoulos Stelios | Option Ex | 120,791 | 5.82 | 703,003 |
| 2020-05-11 | Hessekiel Jeffrey (EVP and General Counsel) | Sale | 38,006 | 27.09 | 1,029,582 |
| 2020-05-11 | Hessekiel Jeffrey (EVP and General Counsel) | Option Ex | 38,006 | 1.90 | 72,211 |
| 2020-05-11 | Marchesi Vincent T | Sale | 30,000 | 26.30 | 789,000 |
| 2020-05-11 | Marchesi Vincent T | Option Ex | 30,000 | 4.58 | 137,400 |
| 2020-05-08 | Haley Patrick J. (EVP, Commercial) | Sale | 21,375 | 25.87 | 552,971 |
| 2020-05-08 | Haley Patrick J. (EVP, Commercial) | Option Ex | 21,375 | 1.76 | 37,620 |
| 2020-05-08 | Senner Christopher J. (EVP and CFO) | Sale | 78,583 | 25.81 | 2,028,227 |
| 2020-05-08 | Senner Christopher J. (EVP and CFO) | Option Ex | 78,583 | 3.66 | 287,613 |
| 2020-05-08 | Hessekiel Jeffrey (EVP and General Counsel) | Sale | 25,000 | 26.04 | 651,000 |
| 2020-05-08 | Hessekiel Jeffrey (EVP and General Counsel) | Option Ex | 25,000 | 1.90 | 47,500 |
| 2020-05-08 | Papadopoulos Stelios | Sale | 45,000 | 25.84 | 1,162,800 |
| 2020-05-08 | Papadopoulos Stelios | Option Ex | 45,000 | 5.25 | 236,250 |
| 2020-05-07 | Senner Christopher J. (EVP and CFO) | Sale | 21,417 | 25.80 | 552,558 |
| 2020-05-07 | Senner Christopher J. (EVP and CFO) | Option Ex | 21,417 | 3.66 | 78,386 |
| 2020-05-07 | Hessekiel Jeffrey (EVP and General Counsel) | Sale | 30,000 | 25.61 | 768,300 |
| 2020-05-07 | Hessekiel Jeffrey (EVP and General Counsel) | Option Ex | 30,000 | 1.90 | 57,000 |
| 2020-05-07 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 50,000 | 25.54 | 1,277,000 |
| 2020-05-07 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 50,000 | 5.51 | 275,500 |
| 2020-05-07 | Feldbaum Carl B | Sale | 31,546 | 25.02 | 789,280 |
| 2020-05-07 | Feldbaum Carl B | Option Ex | 31,546 | 4.60 | 145,111 |
| 2020-05-07 | Poste George | Sale | 30,000 | 25.61 | 768,300 |
| 2020-05-07 | Poste George | Option Ex | 30,000 | 5.82 | 174,600 |
| 2020-05-06 | Morrissey Michael (President and CEO) | Option Ex | 285,284 | 1.70 | 484,982 |
| 2020-04-27 | Morrissey Michael (President and CEO) | Option Ex | 285,000 | 1.70 | 484,500 |
| 2020-04-24 | Scangos George A | Sale | 15,000 | 26.24 | 393,600 |
| 2020-04-23 | Haley Patrick J. (EVP, Commercial) | Sale | 5,000 | 26.00 | 130,000 |
| 2020-04-23 | Haley Patrick J. (EVP, Commercial) | Option Ex | 5,000 | 1.70 | 8,500 |
| 2020-04-23 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Sale | 100,000 | 26.00 | 2,600,000 |
| 2020-04-23 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Option Ex | 100,000 | 1.70 | 170,000 |
| 2020-04-23 | Scangos George A | Sale | 100,000 | 25.95 | 2,595,500 |
| 2020-04-23 | Morrissey Michael (President and CEO) | Option Ex | 250,000 | 5.51 | 1,377,500 |
| 2020-04-22 | Scangos George A | Sale | 4,200 | 25.05 | 105,210 |
| 2020-04-21 | Scangos George A | Sale | 5,800 | 25.04 | 145,232 |
| 2020-04-21 | Morrissey Michael (President and CEO) | Option Ex | 220,000 | 5.51 | 1,212,200 |
| 2020-04-20 | Haley Patrick J. (EVP, Commercial) | Sale | 5,000 | 24.00 | 120,000 |
| 2020-04-20 | Haley Patrick J. (EVP, Commercial) | Option Ex | 5,000 | 1.70 | 8,500 |
| 2020-04-20 | Scangos George A | Sale | 50,000 | 24.05 | 1,202,650 |
| 2020-04-20 | Morrissey Michael (President and CEO) | Option Ex | 240,000 | 5.51 | 1,322,400 |
| 2020-04-15 | Scangos George A | Sale | 25,000 | 18.31 | 457,749 |
| 2020-04-08 | Scangos George A | Sale | 7,065 | 18.35 | 129,642 |
| 2020-04-07 | Scangos George A | Sale | 16,435 | 18.25 | 299,938 |
| 2020-04-06 | Lamb Peter (EVP, Scientific Strategy & CSO) | Sale | 50,000 | 17.26 | 863,000 |
| 2020-04-06 | Lamb Peter (EVP, Scientific Strategy & CSO) | Option Ex | 50,000 | 5.51 | 275,500 |
| 2020-04-03 | Wyszomierski Jack L | Sale | 13,848 | 16.57 | 229,461 |
| 2020-04-03 | Wyszomierski Jack L | Option Ex | 45,000 | 5.25 | 236,250 |
| 2020-03-31 | Scangos George A | Sale | 1,500 | 18.06 | 27,089 |
| 2020-03-20 | Haley Patrick J. (EVP, Commercial) | Sale | 4,318 | 15.37 | 66,367 |
| 2020-03-04 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Sale | 100,000 | 19.40 | 1,939,999 |
| 2020-03-04 | Schwab Gisela (Pres, Prod Dev & Med Aff & CMO) | Option Ex | 100,000 | 1.70 | 170,000 |
| 2020-03-04 | Morrissey Michael (President and CEO) | Option Ex | 50,000 | 5.51 | 275,500 |
| 2020-03-03 | Feldbaum Carl B | Sale | 38,000 | 18.63 | 707,940 |
| 2020-03-03 | Feldbaum Carl B | Option Ex | 38,000 | 5.20 | 197,600 |
| 2020-02-28 | Cohen Charles | Option Ex | 45,000 | 5.25 | 236,250 |
Insider trading activities including stock purchases, stock sales, and option exercises of EXEL listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Exelixis, Inc. (symbol EXEL, CIK number 939767) see the Securities and Exchange Commission (SEC) website.